The Top 5 Biosimilars Articles for the Week of February 5

February 9, 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 5, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 5.

Number 5: According to a new review of the literature, managed care professionals can help providers to personalize treatment for patients with macular degeneration, and can encourage adherence.

Number 4: A recent cross-sectional study found that the uptake of biosimilars in the United Kingdom has been highly variable and generally lower than expected.

Number 3: Sales of MabThera dropped sharply due to competition from biosimilars in the European Union.

Number 2: YL Biologics has reported positive phase 3 clinical trial results for its proposed biosimilar referencing Erelzi.

Number 1: The American College of Rheumatology has released a new white paper that supports the use of biosimilars in clinical practice.

Also this week, Dr Robert Levin, a practicing rheumatologist and patient advocate, wrote in The Center for Biosimilars® that, if HHS wants to confront the problem of high drug prices, it must address the growing role of pharmacy benefit managers.

Finally, last week, our e-newsletter asked whether physicians’ expectations of clinical trials are hindering biosimilar acceptance.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.